Granules India announced on Tuesday that its US subsidiary, Granules Pharmaceuticals, Inc (GPI), has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug

Biocon share price jumped nearly 4 percent during early trades as the company received FDA approval for biosimilar drug Yesintek. Biocon touched intraday high of Rs 380 after opening at Rs 375.

Abbott has won approval for its quick coronavirus test from the US government, the company informed on Friday.